AI Powered Microbiome Discovery and Understanding
Beyond 16S and Shotgun Metagenomics Technologies
Our validated and proprietary Titan-1™ platform for studying the microbiome is a generation ahead of the latest 16S and shotgun metagenomics based approaches in use today. It starts with a patented assay and ends with proprietary Artificial Intelligence (AI) tools for incredibly powerful insights and discoveries across even the largest datasets.
Titan-1™ is being deployed through collaborations with pharma and academic organizations to help drug development and biomarker discovery for therapeutic and diagnostic purposes. Showing the power and utility of our technology, we also work with commercial lab partners, who are using the technology to help patients in ways ranging from improving gut function to wound management.
Breakthrough Data + Breakthrough Analysis = Breakthrough Results
Intus Bio is unique in the AI-driven discovery field. We recognize that the standard approaches do not produce the data required for even the best analysis to generate meaningful microbiome discoveries.
We designed the Titan-1™ assay to be high resolution, high throughput, and database independent. When combined with our advanced AI analysis, it results in high accuracy and actionable information.
Having built a true ‘sample to solution’ or ‘assay to answer’ platform, we control every step of the process, from the lysis used to prepare samples, to deep AI driven analysis of industry leading datasets. This approach, and the quality of results it generates, sets us apart.
The Intus Bio Advantage
Our Titan-1™ Platform Produces Strain Level Data at Scale
Unlike Intus Bio, almost all technologies available today produce only genus and species level results – not strains. Strains are the fundamental unit of the microbiome. Identifying and tracking strains is the key to actionable results.
For example:
- One strain of Lactobacillus can be a key biomarker for drug response or disease diagnosis, while another could play no role
- One strain of E. coli can be a commensal, another a lethal pathogen
Intus Bio’s Titan-1™ platform is unique in that it can immediately identify and track strains – whether they have been previously sequenced or not. Other approaches to differentiating novel strains are costly, data intensive and time consuming.
Intus Bio’s platform produces results with speed, accuracy and scalability, and is unique in its ability to produce strain level information for known and unknown strains.
Proven, Proprietary Technology, Delivering Unmatched Results
Intus Bio’s patented 16S-ITS-23S amplicon powers our Titan-1™ platform, generating enough information to differentiate strains without having to sequence the whole genome.
Our unique approach considers the multiple copies of the 16S-ITS-23S region individually, creating a bacterial strain’s unique composite “fingerprint”. These fingerprints enable strain-level identification and tracking for known and novel strains.
Proprietary software and analysis tools then track the fingerprints to find a particular strain, discover important bacteria across whole populations, or produce individual sample reports on a whole sample basis.